AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00670033 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Travoprost ophthalmic solution, 0.004%
Study NCT00670033 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Inactive ingredients used as a placebo
Study NCT00793117 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: packing
Description: packing in middle meatus for duration of 5 day
Study NCT03802617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MR13A9
Description: Intravenous administration
Study NCT03802617 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous administration
Study NCT03995017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: Rucaparib tablet
Study NCT03995017 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rucaparib
Description: Rucaparib tablet
Study NCT03995017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Ramucirumab intravenous solution
Study NCT03995017 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramucirumab
Description: Ramucirumab intravenous solution
Study NCT03995017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab intravenous solution
Study NCT03297567 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: verbal guidance and a booklet
Description: Patients allocated to the intervention group will receive verbal instruction from the researchers on the importance and benefits of movement during hospital stay, as well as what they should do to increase the level of physical activity. These patients will receive the same guidelines through a playable, easy-to-understand and inexpensive booklet developed by the researchers themselves in PowerPoint 2016 (Microsoft) in order to remedy any doubt or forgetfulness during the hospitalization period
Study NCT02207699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzonatate 200 mg
Description: 2 benzonatate 100 mg perles and 6 placebo perles give by mouth once
Study NCT01573533 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab will be infused intravenously on Day 1 and Day 15 at a dose of 375 mg/m2 up to a maximum of 1000mg per dose in children and at a dose of 1000 mg on Day 1 and Day 15 in adults.
Study NCT03658473 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 550 mg naproxen + 300 mg rebamipide + 20 mg rabeprazole.
Description: Oral administration of 550 mg naproxen 2x daily + 300 mg rebamipide 2x daily + 20 mg rabeprazole 1x daily over 7 days.
Study NCT03658473 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 550 mg naproxen + placebo + 20 mg rabeprazole
Description: Oral administration of 550 mg naproxen 2x daily + placebo of rebamipide 2x daily + 20 mg rabeprazole 1x daily over 7 days.
Study NCT03658473 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 550 mg naproxen + 300 mg rebamipide + placebo
Description: Oral administration of 550 mg naproxen 2x daily + 300 mg rebamipide 2x daily + placebo of rabeprazole 1x daily over 7 days.
Study NCT03658473 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 550 mg naproxen + placebo + placebo
Description: Oral administration of 550 mg naproxen 2x daily + placebo 2x daily + placebo of rabeprazole 1x daily over 7 days.
Study NCT01868763 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: telemedical devices (weighing machine and step counter)
Study NCT01868763 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: care calls once per week for 12 weeks
Study NCT00406588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa (Pardoprunox)
Description: 12-42mg
Study NCT00406588 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Placebo
Study NCT02207699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzonatate 800 mg
Description: 8 benzonatate 100 mg perles given by mouth once
Study NCT02207699 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin 400 mg
Description: 1 moxifloxacin 400 mg tablet given by mouth once
Study NCT02207699 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 8 placebo perles given by mouth once
Study NCT02108951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: Nilotinib 150mg hard gelatin capsules taken orally
Study NCT03391687 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Amylase Test
Description: body fluid amylase will be tested after radical gastrectomy in scheduled interval
Study NCT02678234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol, phenylephrine HCl, and vitamin C
Description: One sachet is provided for each participant randomized to the Theraflu Aktiv powder for oral solution
Study NCT01787643 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Height-Adjustable Desk Intallation in Office
Study NCT02782871 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pneupac VR1
Description: A portable mechanical ventilator/resuscitator for medical personnel in the hospital, ambu-lance, fire, and police services.
Study NCT00276978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Addition of Aripiprazole 10 mg to concurrent medication
Study NCT00379223 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: vitrectomy with radial optic neurotomy
Study NCT01253044 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: Acceptance and Commitment Therapy, delivered twelve 60-minute one-on-one treatment sessions over 6-10 weeks (additional weeks are permissible if needed).
Study NCT01253044 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Present Centered Therapy
Description: Present Centered Therapy, delivered twelve 60-minute one-on-one treatment sessions over 6-10 weeks (additional weeks are permissible if needed).
Study NCT03870126 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Flavored beverage
Description: Consume one beverage at the beginning of each visit of the cross-over sequence
Study NCT03870126 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flavored beverage
Description: Consume one beverage at the beginning of each visit of the cross-over sequence
Study NCT03273205 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Description: This group gets a real stimulation
Study NCT03273205 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: This group gets a sham stimulation
Study NCT01422811 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multicomponent strategy to reduce avoidable length of stay
Description: The strategy comprises two integrated components:~1. Distribution of two monthly reports, one consisting in the list of patients who, through data collection performed, are classified to be present on the ward although their clinical status is considered compatible with discharge; the other featuring individual length of stay profiles for each physician operating in the intervention arm (information taken from administrative data), allowing comparisons with the rest of the medical staff;~2. Audits performed by professionals of each ward of the intervention arm designed to discuss cases judged to be compatible with discharge. The organization of this work are left to the wards, without any interference from the project team.
Study NCT01422811 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Description: No interventions (reporting, auditing) are planned; nevertheless control ward physicians know study aims and are informed about their patient's data collection.
Study NCT03957655 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SHED group
Description: 1x10E6 MSCs/kg body weight will be administered via peripheral vein for 4 times at week 0,4,8,12
Study NCT01076842 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin-Levemir
Description: Levemir once daily, force titrated to reach a fasting plasma glucose of 100 mg/dl
Study NCT01076842 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide-Bayetta
Description: Exenatide twice daily, started at a dose of 5 mcg b.i.d. and increased to 10 mcg b.i.d. after 2 weeks if the fasting plasma glucose of 100 mg/dl is not reached. Exenatide will be administered immediately before breakfast and dinner meals. No further increase in the dose of exenatide will take place. For those who are unable to tolerate exenatide at a 10 mcg b.i.d. dose, it will be reduced to 5 mcg b.i.d. and continued until week 12.
Study NCT01076842 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin-Levemir and Exenatide-Bayetta
Description: Patients from either Group A or Group B who have not reached the goal A1C of 6.5% will be assigned to this Group. They will receive the drug assigned to the other group in addition to the one they were originally assigned.
Study NCT01076842 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SenseWear Pro3® armband
Description: For one-week prior to beginning the assigned medication and for one week , week 11 and week 23, the patients will wear the SenseWear Pro3® armband for collection of ancillary physiologic data
Study NCT01076842 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DexCom CGM
Description: For one-week prior to beginning the assigned medication and for one week , week 11 and week 23, the patients will wear the DexCom CGM for collection of continuous blood glucose concentrations.
Study NCT02143284 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopy exploratory single arm (EndoChoice FUSE(TM) System)
Description: The investigational device will be applied in otherwise standard procedures (upper and lower Gastrointestinal tract endoscopy)
Study NCT04120207 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based Pilates
Description: The Home-based Pilates group will complete two Pilates classes at home, twice weekly, for a period of eight weeks.
Study NCT04120207 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Delayed-start Pilates
Description: The Delayed-start group will maintain their regular daily activities, and be provided with a copy of the Pilates DVD following the intervention, for their own use.
Study NCT00307515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fibrin Sealant 2 (FS2)
Description: FS2 Surgical Sealant Kit: Biological Active Component containing Human Fibrinogen 55-85 mg/mL and Thrombin containing Thrombin 800-1200 IU/mL and Calcium Chloride 5.6-6.2 mg/mL
Study NCT00307515 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oxidized Regenerated Cellulose (Surgicel)
Description: Commercially available Surgicel used within label.
Study NCT05263102 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vaginal Moisturizing Gel
Description: All eligible subjects will received the Vaginal Moisturizing Gel twice per week, total in 8 weeks
Study NCT04013438 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Strogen
Description: The OCP-LD begins in 2 to 3 days of the last menstrual cycle and then 500 μgr/d GnRH-a will received on day 17 for fourteen days. Then in 2-3 days of the next menstrual cycle, GnRH-a reduced to 200 μgr/d dose. the patients will receive 6 mg oral that will be continued for 14 days and during this time endometrium thickness evaluated by vaginal ultrasonography. If endometrial thickness is estimated ≥7mm, intramuscularly progesterone 100 mg/d will be started. After the onset of progesterone (days 17 to 18 cycles) frozen embryos transferred. Control group receive 6 mg oral estrogen and 100 mg intramuscularly progesterone until 12 week of pregnancy. The levels of maternal estrogen and progesterone was measured at the time of the starting day of progesterone (day 15), the day of embryo transfer, 6 and 12 weeks of pregnancy.
Study NCT04013438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Strogen
Description: The OCP-LD begins in 2 to 3 days of the last menstrual cycle and then 500 μgr/d GnRH-a will received on day 17 for fourteen days. Then in 2-3 days of the next menstrual cycle, GnRH-a reduced to 200 μgr/d dose. the patients will receive 6 mg oral that will be continued for 14 days and during this time endometrium thickness evaluated by vaginal ultrasonography. If endometrial thickness is estimated ≥7mm, intramuscularly progesterone 100 mg/d will be started. After the onset of progesterone (days 17 to 18 cycles) frozen embryos transferred. In patients 35 days after embryo transfer and observation of gestational sac with heart beat (6 weeks of pregnancy) by ultrasound, exogenous estrogen will discontinued while progesterone will remain daily use until twelfth week of pregnancy. The levels of maternal estrogen and progesterone was measured at the time of the starting day of progesterone (day 15), the day of embryo transfer, 6 and 12 weeks of pregnancy.
Study NCT01241669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E5555
Description: Drug: Oral E5555 400 mg/matching placebo, oral metformin 500 mg, iohexal 20 mL intravenous (IV), and para-aminohippuric acid (PAH) 7 mg/kg IV.
Study NCT01241669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E5555
Description: Drug: Oral E5555 100 mg/matching placebo, oral metformin 500 mg, iohexal 20 mL intravenous (IV), and para-aminohippuric acid (PAH) 7 mg/kg IV bolus.
Study NCT00850018 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Monthly blood transfusion regimen
Description: Participants will receive blood transfusions at 3- to 4-week intervals for 6 months for the treatment of SCD-related anemia; the total number of transfusions that participants will receive will vary between six and eight.
Study NCT00850018 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Participants will receive usual care for the treatment of SCD.
Study NCT02617732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tianqi capsule
Description: The patients with type 2 diabetes are divided into two groups, one is experimental group, and the other is placebo group.~The experimental group patients are treated with Tianqi capsule by oral, 5 pills three times a day
Study NCT02617732 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The patients with type 2 diabetes are divided into two groups, one is experimental group, the other is placebo group.~The placebo group patients are treated with placebo by oral, 5 pills three times a day
Study NCT02304783 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piroxicam
Description: Patients allocated to this arm received, as a second line treatment of renal colics, a five days treatment with 20 mg piroxicam associated with placebo per day and were contacted at the seventh day by telephone call to investigate the efficacity and the side effects of the treatment.
Study NCT02304783 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients allocated to this arm received a five days treatment with Placebo and were contacted at the seventh day by telephone call to investigate the efficacity and the side effects of the treatment.
Study NCT02304783 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paracetamol
Description: Patients allocated to this arm received a five days treatment with Paracetamol and were contacted at the seventh day by telephone call to investigate the efficacity and the side effects of the treatment.
Study NCT03759457 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Flow Nasal Cannula (AIRVO2)
Description: High-flow nasal cannula (HFNC) delivers oxygen flows of up to 60 L/min. The gas source (air/oxygen blender, ventilator, or turbine flow-generator) is connected via an active heated humidifier to a nasal cannula and allows FiO2 adjustment independently from the flow
Study NCT04281160 — intervention group
Intervention type: DEVICE
Intervention: BeCare Mobile App
Description: The BeCare App is a mobile application that will perform routine assessments of neurological function in individuals with MS and address the most relevant domains that are affected in MS: cognition, afferent visual functioning, motor functioning, fine motor functioning, coordination, gait, and endurance
Study NCT02096146 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: TMT Fusion plate
Description: Patients are treated with TMT Fusion Plate a post-market device to encourage bony fusion of the 1st TMT joint.
Study NCT02096146 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Two crossed screws
Description: Patients are treated with two crossed screws.This procedure is a standard treatment for 1st TMT joint fusion.
Study NCT01223872 — intervention group
Intervention type: OTHER
Intervention: interview
Description: * Standard Interview (2-15 years from last treatment)~* Demographic data interview (pre-initial study interview)
Study NCT01223872 — intervention group
Intervention type: OTHER
Intervention: clinic visit and interview
Description: * REACH Clinic Visit(initial or regular)~* Post-REACH Clinic Interview (3mos from initial or regular clinic visit)~* Demographic data interview(pre-initial study interview)
Study NCT01223872 — intervention group
Intervention type: OTHER
Intervention: interviews and clinic visit
Description: * Pre-REACH Clinic Interview(2-15 yrs from last treatment)~* REACH Clinic Visit(initial or regular)~* Post-REACH Clinic Interview(1mo from initial clinic visit)~* Post-REACH Clinic Interview(3mos from initial or regular clinic visit)~* Demographic data interview(pre-initial study interview)
Study NCT01457859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triclosan
Description: Triclosan coated surgical sewing threads (VICRYL+ and MONOCRYL+) applied for leg wound closure after CABG
Study NCT01457859 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional non-coated surgical sutures
Description: Conventional non-coated surgical sewing threads (POLYSORB and BIOSYN) will be applied after CABG for leg wound closure
Study NCT01435031 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: CTO Treatment Device
Description: Subjects receiving at least 1 of the following for the treatment of CTO:~* XIENCE V® and/or XIENCE nano™ and/or XIENCE PRIME™ LL Everolimus Eluting Coronary Stent~* HT PROGRESS and/or HT PILOT guide wires in recanalization~* MINI-TREK Coronary Dilatation Catheter in predilatation
Study NCT01130779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib (TARCEVA®)
Description: Erlotinib 150mg/day, everyday
Study NCT02639728 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regular Coffee
Description: Regular coffee will be given a 4oz cup three times daily and will be instructed to consume all of its liquid contents.
Study NCT02639728 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee
Description: Decaffeinated coffee will be given a 4oz cup three times daily and will be instructed to consume all of its liquid contents.
Study NCT02639728 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Warm water
Description: Warm water will be given a 4oz cup three times daily and will be instructed to consume all of its liquid contents.
Study NCT02624167 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NW-3509A
Description: Patients will be given oral doses of 15, 20 and 25 mg BID of NW-3509A
Study NCT00727038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab (Lucentis)
Description: 0.5 mg ranibizumab intravitreal injection single dose administration
Study NCT02624167 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will be given oral dose of matching Placebo
Study NCT00913796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium citrate
Description: 2.41 gram of citrate b.i.d. for 12 months. Dosage to be adjusted according to serum potassium concentration.
Study NCT00913796 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Potassium chloride
Description: 370 mg potassium t.i.d. for 12 months. Dosage to be adjusted according to serum postassium concentration.
Study NCT03242616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed + Vinorelbine
Description: Vinorelbine (25 mg/m2, day 1 \& 8)~* Pemetrexed (500 mg/m2, day 1)
Study NCT03242616 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine
Description: Vinorelbine (25 mg/m2, day 1 \& 8)
Study NCT03699241 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: BG505 SOSIP.664 gp140, adjuvanted
Description: Dosage of 30ug, Intramuscular administration
Study NCT03699241 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: BG505 SOSIP.664 gp140, adjuvanted
Description: Dosage of 100ug, Intramuscular administration
Study NCT03699241 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: BG505 SOSIP.664 gp140, adjuvanted
Description: Dosage of 300ug, Intramuscular administration
Study NCT03699241 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tris-NaCl Diluent
Study NCT00873119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: belinostat, carboplatin, paclitaxel
Study NCT00873119 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin, paclitaxel